Biocon’s Kiran Mazumdar-Shaw says AI can speed drug development
In short
Biocon’s Kiran Mazumdar-Shaw said on Tuesday that AI could cut drug development time from five to seven years to one or two years.
She said faster work from the lab to the clinic could open up more precision and personalised medicine.
What the reporting says
Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Tuesday that artificial intelligence could sharply reduce the time needed to take a drug molecule from the lab to patients. She said the current five-to-seven-year path could be compressed to one or two years. She linked faster lab-to-clinic development to opportunities in precision and personalised medicine.
Why it matters
Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Tuesday that AI may compress drug development timelines from five-to-seven years to one or two years. Her comments focused on the move from lab research to clinical trials and the possible boost for precision and personalised medicine. The statement highlights how AI could affect drugmakers and life sciences workflows if the claimed speed-up is achieved.